Regulatory Focus™ > News Articles > 8 > Pfizer Calls for FDA Guidance to Address False and Misleading Biosimilar Ads

Pfizer Calls for FDA Guidance to Address False and Misleading Biosimilar Ads

Posted 28 August 2018 | By Zachary Brennan 

Pfizer Calls for FDA Guidance to Address False and Misleading Biosimilar Ads

Taking issue with Amgen, Genentech and other reference product sponsors’ dissemination of misleading information on biosimilars, Pfizer is asking the US Food and Drug Administration (FDA) to take action with new guidance on what’s acceptable.

In a citizen petition filed Monday, Pfizer notes examples of what it calls “inappropriate communications” and “misleading representations and suggestions by reference product sponsors.” The issue at hand isn’t so much that the information is wrong, but that the statements imply that biosimilars are not as safe or as effective as reference products.

Pfizer says it has observed some reference product sponsor-created physician- and patient-directed materials that “mischaracterize important elements of the biosimilar criteria and create doubt and confusion about the safety and efficacy of biosimilars.”

For instance, a textual summary comparing biosimilars and generics on a Genentech website explains that
“FDA requires a biosimilar to be highly similar, but not identical to the [reference product],” but Pfizer notes that the explanation “fails to state that an approved biosimilar must have no clinically meaningful differences from the reference product.”

Similarly, an Amgen YouTube video implies that switching to a biosimilar from a reference product is risky, though a recent review found the opposite. Pfizer also points to Remicade ads from Janssen Biotech that failed to mention a biosimilar works in the same way as the reference product.

Request for FDA

In calling for FDA to craft a new guidance on what’s misleading and what isn’t, Pfizer also asks for the guidance to address reference product sponsor communications comparing reference biologics to biosimilars, including interchangeable biosimilars, “that would and would not be considered misleading.

“Promotional statements by a reference product sponsor that directly or implicitly communicate that biosimilar products differ from interchangeable products in any regard beyond the additional data required to permit substitution without physician intervention at the pharmacy level are plainly misleading,” Lisa Skeens, VP of Global Regulatory Affairs at Pfizer, wrote.

Skeens also calls on FDA to target certain ads or promotional materials that sow confusion and mistrust among patients and physicians. And Pfizer also wants FDA to clarify that biosimilar sponsors may discuss clinical and other data with physicians and in promotional materials.

She also notes that while it’s generally out of FDA’s purview, “payer reimbursement policies are in fact impeding adoption of biosimilars,” though “dissemination of false or misleading information about the safety or efficacy of biosimilars, whether to patients and prescribers or directly to payers, has the potential to affect payer decisions about biosimilar reimbursement, as well as patient and healthcare professional confidence in biosimilars.”

Citizen Petition
 

Categories: Regulatory News

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe